Teladoc Health (NYSE:TDOC) Price Target Cut to $25.00

Teladoc Health (NYSE:TDOC) had its price target reduced by investment analysts at Canaccord Genuity Group from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 92.16% from the stock’s previous close.

Several other equities research analysts also recently commented on TDOC. Leerink Partnrs reissued a “market perform” rating on shares of Teladoc Health in a report on Monday, February 26th. DA Davidson lowered their price objective on Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 21st. Piper Sandler dropped their price target on shares of Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Friday. Finally, Barclays lowered their price objective on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.67.

Teladoc Health Stock Down 2.4 %

Shares of Teladoc Health stock opened at $13.01 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. The business has a 50-day moving average of $14.85 and a two-hundred day moving average of $17.72. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The company had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.37) earnings per share. Analysts anticipate that Teladoc Health will post -1.06 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CTO Nikolaos P. Nanis sold 2,866 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the transaction, the chief technology officer now directly owns 69,850 shares in the company, valued at approximately $1,014,222. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jason N. Gorevic sold 53,755 shares of Teladoc Health stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $780,522.60. Following the sale, the chief executive officer now directly owns 653,073 shares in the company, valued at $9,482,619.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Nikolaos P. Nanis sold 2,866 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the sale, the chief technology officer now directly owns 69,850 shares in the company, valued at $1,014,222. The disclosure for this sale can be found here. In the last three months, insiders have sold 135,441 shares of company stock worth $2,038,251. 1.63% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TDOC. ICA Group Wealth Management LLC bought a new stake in Teladoc Health during the fourth quarter worth about $28,000. Hexagon Capital Partners LLC lifted its holdings in shares of Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 1,065 shares during the last quarter. RIA Advisory Group LLC bought a new stake in shares of Teladoc Health in the 4th quarter worth approximately $36,000. GAMMA Investing LLC purchased a new stake in shares of Teladoc Health in the 4th quarter worth approximately $41,000. Finally, Principal Securities Inc. purchased a new stake in shares of Teladoc Health in the 4th quarter worth approximately $45,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.